All News

Found 6,426 articles

• Brand Institute Partners on Brand Name Development for FDA Approved Treatment to Help Retinal Disease Patients Maintain or Gain Vision

  8/8/2022

  Brand Institute is proud to announce its work with Coherus BioSciences in developing the brand name CIMERLI™ (ranibizumab-eqrn), under which the interchangeable biosimilar approved by the Food and Drug Administration (FDA) on August 2, 2022, will be marketed.

• Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022

  8/8/2022

  Amphastar Pharmaceuticals, Inc. reported results for the three months ended June 30, 2022.

• AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022

  8/8/2022

  Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager (HLE BiTE®) molecule targeting delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

• Amgen Data at WCLC 2022 Highlights Potential to Deliver Transformative Medicines for Historically Difficult-to-treat Lung Cancers

  8/7/2022

  Amgen announced three new data sets from its thoracic oncology portfolio that will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer from August 6-9 in Vienna, Austria.

• Amneal Reports Second Quarter 2022 Financial Results

  8/5/2022

  Amneal Pharmaceuticals, Inc. announced its results for the second quarter ended June 30, 2022.

• AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

  8/4/2022

  Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.

• Organon Reports Results for the Second Quarter Ended June 30, 2022

  8/4/2022

  Organon (NYSE: OGN) (the “company”), today announced its results for the second quarter ended June 30, 2022.

• Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

  8/4/2022

  Innovent Biologics, Inc. ("Innovent", HKEX: 01801), and Sanofi announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers.

• Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of APOE4 Genotype on ARIA-E Incidence at the Alzheimer's Association International Conference (AAIC) 2022

  8/4/2022

  Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab and the modeling simulation of the impact of ApoE4 genotype on the incidence of amyloid-related imaging abnormalities.

• Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

  8/4/2022

  Coherus BioSciences, Inc., reported financial results for the quarter ended June 30, 2022 and recent business highlights.

• Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements

  8/4/2022

  Eli Lilly and Company announced its financial results for the second quarter of 2022.

• Amgen Reports Second Quarter 2022 Financial Results

  8/4/2022

  Amgen announced financial results for the second quarter of 2022.

• Cell Culture Media Market Size to Hit USD 10.5 Billion by 2030

  8/4/2022

  According to Vision Research Report, the global cell culture media market size is expected to hit around USD 10.5 billion by 2030, growing at a CAGR of 12.57% from 2022 to 2030

• Cancer Monoclonal Antibodies Market Size USD 159.96 BN by 2030

  8/4/2022

  According to Vision Research Reports, the global cancer monoclonal antibodies market size is expected to hit around USD 159.96 billion by 2030, growing at a CAGR of 11.07% from 2022 to 2030.

• 

  Drug Pricing Debates Heat Up Just in Time for Election Season

  8/3/2022

  The debate over drug pricing tends to heat up during election season. With the mid-terms in November, we’re going through the cycle once again, sparked by provisions in the Inflation Reduction Act.

• Amneal Appoints Deborah M. Autor to Board of Directors

  8/3/2022

  Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that Deborah M. Autor has been appointed to the Company’s Board of Directors, effective July 29, 2022.

• Amgen Announces 2022 Third Quarter Dividend

  8/3/2022

  Amgen announced that its Board of Directors declared a $1.94 per share dividend for the third quarter of 2022.

• Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

  8/3/2022

  Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses.

• FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

  8/2/2022

  Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all five indications, meeting the FDA’s rigorous standards to the reference product, including safety, efficacy and quality.

• Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8009, an Antibody Drug Conjugate Targeting B7-H3 (CD276) for the Treatment of Advanced Solid Tumors

  8/2/2022

  Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8009, an antibody drug conjugate (ADC) that targets B7-H3 (CD276).